Click here for slides on this topic


Plasma

The clear fluid portion of the blood that is free of any type of blood cell.


The following content matched the glossary term: Plasma

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

American Diabetes Association (ADA)/American Geriatrics Society (AGS) Guidelines 2012

Top

Diabetes management guidelines for older adults from the American Diabetes Association (ADA)/American Geriatrics Society (AGS) 

Risk of cardiovascular and all-cause mortality: impact of impaired health-related functioning and diabetes: AusDiab study

Top

Williams ED, Rawal L, Oldenburg BF, Renwick C, Shaw JE, Tapp RJ. Risk of cardiovascular and all-cause mortality: impact of impaired health-related functioning and diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2012;35:1067-1073. In this substudy of the Australian Diabetes, Obesity and Lifestyle (AusDiab) study, Williams and colleagues demonstrated for the first time that combined exposure to type 2 diabetes and health-related functioning is associated with an increased risk of both cardiovascular (CV) and all-cause mortality.

Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk

Top

Guasch-Ferré M, Bulló M, Martínez-González MÁ, Corella D, Estruch R, Covas MI, Arós F, Wärnberg J, Fiol M, Lapetra J, Muñoz MÁ, Serra-Majem L, Pintó X, Babio N, Díaz-López A, Salas-Salvadó J. Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk. PLoS One. 2012;7(8):e43275. Several anthropometric measurements have been associated with cardiovascular disease, type-2 diabetes mellitus and other cardiovascular risk conditions, such as hypertension or metabolic syndrome.

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

Fonseca Commentary

Top

ORIGIN: The Effects of Insulin Glargine and Omega-3 Fatty Acids on Cardiovascular Death in Diabetes or Prediabetes. NDEI.org Education Council Member Vivian A. Fonseca, MD, provides expert commentary on the clinical implications of the ORIGIN omega-3 trial results.

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial

Top

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes an analysis of baseline data from the ORIGIN trialRamachandran A, Riddle MC, Kabali C, Gerstein HC for the ORIGIN Investigators. Diabetes Care. 2012 35 749 753. The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial is a global trial assessing whether targeting normal FPG levels with basal insulin glargine reduces cardiovascular outcomes compared with standard care among people taking 0 or 1 oral antidiabetes drugs (OADs).

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Plasma Slides Found: 142
Glyburide Monotherapy: Effect on Plasma Glucose and Insulin Levels
DPP: Fasting Plasma Glucsose and HbAlc
Association Between Insulin Sensitivity and Physical Exercise The IRAS Study
US DPP Incidence of Type 2 Diabetes With Different Interventions
Adiponectin and CRP Levels in Healthy Obese Women
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Effect of Orlistat on Lipids and Glycemic Control in Patients
Effect of Bariatric Surgery on Acute Insulin Response
Glyburide Monotherapy: Effect on Plasma Glucose and Insulin Levels
DPP: Fasting Plasma Glucsose and HbAlc
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
Type 2 Diabetes in US Adults: Overview
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Regulation of Insulin Secretion
Beta-Cell Adaptation to Insulin Resistance: Longitudinal Data in Normal Women
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
Changing Glucose: Different Rates at Different Clinical Stages
UKPDS: Progressive Deterioration in Glycemic Control Over Time
Fasting Plasma Glucose and the Acute Insulin Response
Acute Insulin Response to Arginine
Decreases in Insulin Response
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Achievement of A1C Levels <7%
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Vildagliptin: Percentage of Patients Achieving A1C <7%
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
DPP: Incidence of Type 2 Diabetes
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Effects of Exenatide LAR on Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
Odds Ratios of In-Hospital Mortality by Admission and Fasting Glucose Levels
Mortality Risk Up to 6-Months in Patients With or Without Diabetes
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
Whitehall II: HOMA Insulin Sensitivity Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Saxagliptin for Treatment of Type 2 Diabetes: Design
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
DPPOS Bridge: Year 4
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Study Design
AusDiab Substudy: Design
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Glycemia, BP, and Dyslipidemia
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
ADA/Endocrine Society: Definition of Hypoglycemia in Diabetes
ADA/Endocrine Society: Classification of Hypoglycemia in Diabetes
ORIGIN-GRACE: Summary of Findings
CANTATA-D2: Design
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significantly Greater Weight Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-M: Significant FPG Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Weight Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Design
ESH/ESC Hypertension Guidelines: Individuals at Higher CV Risk
ESH/ESC Hypertension Guidelines: Laboratory Tests
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
Metformin: Renal Considerations
Liraglutide Enhances Glucose-Dependent Insulin Secretion
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
LEAD 6: Change in FPG at 26 Weeks
LEAD 6: Change in Weight at 26 Weeks
IDF 2012 Type 2 Diabetes Guidelines Screening Diagnosis | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Glycemic Control | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Diabetes Pregnancy Guidelines Diabetes Testing Endocrine Society | NDEI
Diabetes Pregnancy Guidelines GDM Testing Endocrine Society | NDEI
Dapagliflozin Pharmacokinetics in Type 1 Diabetes SGLT 2 | NDEI
Average Daily Glucose Changes & Insulin Use Dapagliflozin Type 1 Diabetes | NDEI
ADA Type 1 Diabetes Guidelines Diagnostic Criteria | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
AACE 2015 Guidelines Criteria for Diagnosing Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
AACE 2015 Guidelines In-Patient Glycemic Targets Critically Ill A1C | NDEI
AACE 2015 Diabetes Guidelines Gestational Diabetes Diagnosis PPT | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Type 2 Diabetes Screening US Preventive Type 2 Diabetes Guidelines | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Criteria for Type 2 Diabetes Diagnosis ADA Guidelines 2016 | NDEI PPT
Prediabetes Increases Type 2 Diabetes Risk ADA Guidelines | NDEI PPT
Glycemic Targets for Adults With Diabetes A1C ADA Guidelines | NDEI
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
Correlation of A1C With Average Glucose ADA Guidelines | NDEI PPT
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI